Cipla reported INR8.88B in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Arca Biopharma USD -36.43M 2M Mar/2026
aTyr Pharma USD -128K 24.6M Mar/2026
Bio Path USD -297K 191K Mar/2026
Brainstorm Cell Therapeutics USD -2.05M 198K Mar/2026
Capricor Therapeutics USD -29.16M 2.87M Dec/2025
Cara Therapeutics USD -7.05M 1.11M Mar/2026
Cipla INR 8.88B 2.74B Jun/2026
Dr.Reddys Laboratories INR 3.25B 2.36B Jun/2026
Immunic USD -23.33M 2.67M Dec/2025
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sun Pharmaceuticals INR 35.57B 8.05B Jun/2026
TherapeuticsMD USD -1.18M 40K Jun/2024
UPL INR 6.68B 20.64B Jun/2026